Fallopian Tube Neoplasms: all 734 studies
Page 5 of 8. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.
- First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.SuspendedNCT04711161Phase 1
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04673448Phase 1
- Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerActive, not recruitingNCT04575961Phase 2
- Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian CancerStatus unknownNCT04556071Phase 2
- Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian CancerCompletedNCT04546373
- Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer PatientsCompletedNCT04537702Not applicable
- Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian CancerWithdrawnNCT04510584Phase 2
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1
- Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryActive, not recruitingNCT04498117Phase 3
- A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesCompletedNCT04440943Phase 1
- Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & SurvivalStatus unknownNCT04402333
- Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04387227Phase 2
- SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer CareWithdrawnNCT04368130Not applicable
- National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
- Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceRCompletedNCT04295577
- Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their RelativesCompletedNCT04257045
- A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
- Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsCompletedNCT04227522Phase 3
- Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric PatientsTerminatedNCT04213794Early Phase 1
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant ChemotherapyActive, not recruitingNCT04204811Not applicable
- High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral NeuropathyActive, not recruitingNCT04201561Phase 3
- Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04095364Phase 3
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerStatus unknownNCT04029909Phase 1
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- Genomic BRCA and Extensive ovArian Cancer TestingCompletedNCT04027868
- A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced CancersTerminatedNCT04025216Phase 1
- Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryActive, not recruitingNCT03943173Early Phase 1
- Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
- Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian CancerTerminatedNCT03922776Not applicable
- The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian CancerCompletedNCT03921658
- Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerActive, not recruitingNCT03907527Phase 1
- DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal CarcinomaWithdrawnNCT03905902Phase 3
- Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological CancerWithdrawnNCT03902379Not applicable
- Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)TerminatedNCT03891576Phase 2
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedNCT03872947Phase 1
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
- Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian TubeActive, not recruitingNCT03771651Early Phase 1
- Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersCompletedNCT03748186Phase 1
- Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT03735589Phase 1/2
- Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal CancerStatus unknownNCT03693248Phase 3
- Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03691376Phase 1
- Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 2
- Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyWithdrawnNCT03607955Phase 1
- Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal CancersCompletedNCT03604653
- Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03586661Phase 1
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
- Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in IndiaCompletedNCT03471572
- Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva CombinationStatus unknownNCT03462212Phase 1/2
- Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube CancerStatus unknownNCT03410784Phase 2
- Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)Active, not recruitingNCT03393884Phase 1/2
- Debulking Surgery in Ovarian CancerCompletedNCT03378128Not applicable
- Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive SurgeryStatus unknownNCT03373058Phase 3
- The Treatment Preferences of Women Diagnosed With Ovarian CancerCompletedNCT03367260
- BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
- BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasActive, not recruitingNCT03355976Phase 2
- Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal CancerCompletedNCT03332576Phase 1
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
- Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine CancerCompletedNCT03325634Phase 1
- Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer PatientsStatus unknownNCT03321188Phase 2
- PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.Status unknownNCT03283943Phase 1
- Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal IntCompletedNCT03213964Phase 1
- Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid TumorsTerminatedNCT03189108
- Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian CancerStatus unknownNCT03188159Phase 2
- Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian CancerStatus unknownNCT03180177Phase 3
- Homologous Recombination Inquiry Through Ovarian Malignancy InvestigationsCompletedNCT03159572
- Biomarkers for Early Detection of Ovarian Cancer Using Uterine LavageStatus unknownNCT03150121Not applicable
- Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerCompletedNCT03126812Phase 1/2
- Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT03056833Phase 1
- A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube CancerCompletedNCT03030287Phase 1
- Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT03029403Phase 2
- Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03017131Phase 1
- HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeStatus unknownNCT03000192
- Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerCompletedNCT02996825Phase 1
- Determinants of Age-Related Treatment Effectiveness in Ovarian CancerCompletedNCT02973750
- Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative StudyCompletedNCT02928549
- Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype PatientsCompletedNCT02903004Phase 3
- Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look SurgeryActive, not recruitingNCT02884648Phase 2
- PET Imaging of Ovarian Carcinoma With 18F-FSPGWithdrawnNCT02872519Early Phase 1
- Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer (SUNNY)Active, not recruitingNCT02859038Phase 3
- Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT02833506Phase 1
- A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic CancersCompletedNCT02824328
- Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving ChemotherapyCompletedNCT02786524Not applicable
- Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian CancerActive, not recruitingNCT02785250Phase 1/2
- Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)WithdrawnNCT02756130Phase 1/2
- Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and TaxaneCompletedNCT02728622Phase 3
- Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)Active, not recruitingNCT02726997Phase 1/2
- Pilot Study of Durvalumab and Vigil in Advanced Women's CancersCompletedNCT02725489Phase 2
- LCC-CARIS-01: Molecular Profiling in Gynaecological CancerCompletedNCT02668913Not applicable
- Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02659241Early Phase 1
- Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1
- Total/Subtotal Colectomy in Ovarian CancerStatus unknownNCT02595021Phase 2
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerActive, not recruitingNCT02571725Phase 1/2
- Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian CancerStatus unknownNCT02534922Phase 1
- A Study of Long-Term Responders on OlaparibCompletedNCT02489058
- A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube CancerActive, not recruitingNCT02489006Phase 2
- HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian CarcinomaWithdrawnNCT02487849Phase 2
- Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian CancerCompletedNCT02480374Phase 1
- DNA Single Nucleotide Polymorphisms as Predictors of ToxicityStatus unknownNCT02478476